Pharma Focus America

Pharma Focus America Welcome to Pharma focus America! We bring you the latest insights, innovations, and news from the world of pharmaceuticals. Ltd..

Join our community to stay updated and engage with industry experts! About Pharma Focus America:
Pharma Focus Aerica is a half yearly publication from Ochre Media Pvt. It is the leading pharma title in print and digital versions serving the information needs of key executives from the world’s leading pharmaceutical companies. Pharma Focus America covers important issues and trends shaping the future of the pharma industry across America and rest of the world. Pharma Focus America offers . . .
• Dedicated, reliable and accurate coverage of the industry’s progress and
• Incisive analysis to help its readers make informed decisions to stay ahead of the competition. The magazine provides cutting-edge and futuristic content on the pharma industry. The issues are broadly categorized into various sections:
• Strategy
• Research and Development
• Manufacturing
• Clinical Trials
• Information Technology

The one-stop pharma destination www.pharmafocusamerica.com features complete content from the Pharma Focus America magazine. Also find the latest pharma news, press releases, pharma industry reports, interviews, trends and pharma events updated on a daily basis. The magazine is supplemented by the monthly e-Newsletter: Verticaltalk Pharma. The readership
The magazine’s readership includes the top C-level executives, senior industry executives, and key decision makers from the pharma industry in charge of spending. With a special focus on America, Pharma Focus America reaches out to the key industry leaders across America, Europe and the Asia.

RNA therapeutics are transforming healthcare—but can manufacturing keep up?In Pharma Focus America Issue 07, 𝐒𝐭𝐞𝐟𝐚𝐧 𝐋𝐮𝐭𝐳...
02/04/2026

RNA therapeutics are transforming healthcare—but can manufacturing keep up?

In Pharma Focus America Issue 07, 𝐒𝐭𝐞𝐟𝐚𝐧 𝐋𝐮𝐭𝐳, 𝐏𝐡𝐃 (𝐂𝐒𝐎, 𝐂𝐨𝐝𝐞𝐱𝐢𝐬), breaks down how enzyme-enabled biocatalysis is changing the way RNA drugs are produced—making them more scalable, efficient, and sustainable.

As demand rises for treatments targeting millions of patients, traditional methods are being pushed to their limits. The future lies in smarter, cleaner, and more adaptable manufacturing approaches.

𝐆𝐞𝐭 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬—𝐝𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐞𝐛𝐨𝐨𝐤 𝐭𝐨𝐝𝐚𝐲:
https://www.pharmafocusamerica.com/magazine

👉 𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞 𝐧𝐨𝐰 𝐭𝐨 𝐫𝐞𝐚𝐝 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐈𝐬𝐬𝐮𝐞 𝟎𝟕:
https://www.pharmafocusamerica.com/manufacturing/redefining-rna-manufacturing-through-innovation

Why is manufacturability becoming a game-changer in API development?In Pharma Focus America – Issue 07, Peter McDonald (...
01/04/2026

Why is manufacturability becoming a game-changer in API development?

In Pharma Focus America – Issue 07, Peter McDonald (Director of Process Development Services, Thermo Fisher Scientific) shares how smarter process design can reduce costs, improve safety, and ensure consistent drug quality—ultimately benefiting patients.

From simplifying complex synthesis to improving sustainability and minimizing waste, manufacturability is shaping how modern medicines are developed and delivered.

💡 Want to stay informed on the latest pharma trends?

Read the full article: https://www.pharmafocusamerica.com/manufacturing/the-increasing-importance-of-manufacturability

Download the newest eBook now: https://www.pharmafocusamerica.com/magazine

The GLP-1 boom is changing the rules of pharma supply chains. Dr. Stefan Kahl, Director at BearingPoint, shares in Pharm...
31/03/2026

The GLP-1 boom is changing the rules of pharma supply chains. Dr. Stefan Kahl, Director at BearingPoint, shares in Pharma Focus America, Issue 07, why 2026 success depends on orchestration—not just building capacity.

From API production to injection devices, end-to-end system management is now the key differentiator. Organizations that integrate, synchronize, and govern their entire supply chain will lead the market.

Learn how to stay ahead and turn operational complexity into competitive advantage.

𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: https://www.pharmafocusamerica.com/research-development/glp-1-at-scale-why-2026-will-reward

Download the latest magazine: https://www.pharmafocusamerica.com/magazine

Why do so many promising drugs fail—even after years of research?In 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐈𝐬𝐬𝐮𝐞 𝟎𝟕, Gaomai (Michael) Yang...
30/03/2026

Why do so many promising drugs fail—even after years of research?

In 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐈𝐬𝐬𝐮𝐞 𝟎𝟕, Gaomai (Michael) Yang from Glycogene Inc shares a powerful new perspective on fixing this challenge.

Instead of abandoning failed molecules, what if we redesign them?

🔬 New therapeutic models like:
• Antibody + Drug + Third Party
• Antibody + siRNA/ASO + Third Party

…are opening doors to:
✅ Better targeting
✅ Lower toxicity
✅ Stronger anti-tumor effects

Even compounds once limited by toxicity—like Exatecan—are finding new life through smarter design.

📖 This isn’t just innovation—it’s rethinking the entire system.

https://www.pharmafocusamerica.com/research-development/antibody-drug-third-party-antibody

👉 𝐆𝐞𝐭 𝐲𝐨𝐮𝐫 𝐜𝐨𝐩𝐲 𝐨𝐟 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐈𝐬𝐬𝐮𝐞 𝟎𝟕 𝐭𝐨𝐝𝐚𝐲—𝐝𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐞𝐁𝐨𝐨𝐤 𝐟𝐫𝐨𝐦 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://www.pharmafocusamerica.com/magazine

PROCOS has reached a major milestone in its growth journey with the completion and regulatory approval of R11, a new sta...
30/03/2026

PROCOS has reached a major milestone in its growth journey with the completion and regulatory approval of R11, a new state-of-the-art multipurpose GMP manufacturing facility. www.procos.it

With an investment exceeding €60 million, R11 significantly expands our capacity and flexibility in small-molecule API manufacturing, supporting clinical and commercial supply while meeting the highest quality and sustainability standards.

Designed to adapt to evolving market and regulatory needs, R11 reinforces PROCOS’ long-term strategy focused on innovation, operational excellence, and responsible growth. This achievement further strengthens our position as a trusted CDMO partner worldwide. www.procos.it

Indonesia is stepping into the spotlight as a fast-growing hub for clinical trials—and the pace of change may surprise y...
30/03/2026

Indonesia is stepping into the spotlight as a fast-growing hub for clinical trials—and the pace of change may surprise you.

This March 31, join an insightful session featuring the Minister of Health, Republic of Indonesia, sharing a direct perspective on where the country’s clinical development ecosystem is headed.

🗓 𝐌𝐚𝐫𝐜𝐡 𝟑𝟏, 𝟐𝟎𝟐𝟔
🕔 𝟓:𝟎𝟎 𝐏𝐌 𝐄𝐃𝐓

You’ll hear about:
✅ Real progress over the last three years
✅ What sponsors should consider before entering Indonesia
✅ Regulatory updates and operational insights
✅ Why Indonesia is becoming a key player in APAC trials

If your team is evaluating global trial locations or watching APAC trends, this conversation is worth your time.

👉 𝐒𝐚𝐯𝐞 𝐲𝐨𝐮𝐫 𝐬𝐞𝐚𝐭 𝐭𝐨𝐝𝐚𝐲—https://industry.pharmafocusamerica.com/clientemailblast/1774594053-IQVIA-2.html

PROCOS has reached a major milestone in its growth journey with the completion and regulatory approval of R11, a new sta...
27/03/2026

PROCOS has reached a major milestone in its growth journey with the completion and regulatory approval of R11, a new state-of-the-art multipurpose GMP manufacturing facility. www.procos.it

With an investment exceeding €60 million, R11 significantly expands our capacity and flexibility in small-molecule API manufacturing, supporting clinical and commercial supply while meeting the highest quality and sustainability standards.

Designed to adapt to evolving market and regulatory needs, R11 reinforces PROCOS’ long-term strategy focused on innovation, operational excellence and responsible growth. This achievement further strengthens our position as a trusted CDMO partner worldwide. www.procos.it

The way we approach obesity care is changing—fast. GLP-1 therapies are no longer just a treatment; they’re part of a big...
27/03/2026

The way we approach obesity care is changing—fast. GLP-1 therapies are no longer just a treatment; they’re part of a bigger, behavior-first approach that drives lasting results.

Dr. Nicholas Syhler, MD MBA, shares insights from real-world programs showing that combining GLP-1s with coaching and lifestyle support:
🌟 Boosts adherence
🌟 Helps patients sustain weight loss
🌟 Reduces costs while improving health outcomes

Patients can achieve trial-level results with less medication, and 78.5% maintain weight loss after stopping GLP-1s.

Learn how your organization can adopt GLP-1 therapies strategically for long-term success.

🔗 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞: https://www.pharmafocusamerica.com/expert-talk/glp-1-therapies-in-real-world-weight-care-provider

The CDMO industry is changing—and fast.In 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐈𝐬𝐬𝐮𝐞 𝟎𝟕, industry experts Ralf Dillmann and Dr. Stefan K...
26/03/2026

The CDMO industry is changing—and fast.

In 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐈𝐬𝐬𝐮𝐞 𝟎𝟕, industry experts Ralf Dillmann and Dr. Stefan Kahl share a grounded perspective on what’s really happening post-pandemic. The hype around pricing power is fading, replaced by a sharper focus on reliability, compliance, and smart investments.

📊 𝐖𝐡𝐚𝐭’𝐬 𝐝𝐫𝐢𝐯𝐢𝐧𝐠 𝐭𝐡𝐞 𝐬𝐡𝐢𝐟𝐭?
✔️ Reshoring and regional supply chains
✔️ Growing complexity in biologics and advanced therapies
✔️ Increasing regulatory scrutiny
✔️ Sponsors choosing trusted, proven partners

The future belongs to CDMOs that deliver consistent quality—not just capacity.

𝐖𝐚𝐧𝐭 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬?
https://www.pharmafocusamerica.com/strategy/navigating-the-us-cdmo-industry

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐞𝐁𝐨𝐨𝐤 𝐧𝐨𝐰 𝐟𝐫𝐨𝐦 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞 𝐚𝐧𝐝 𝐬𝐭𝐚𝐲 𝐚𝐡𝐞𝐚𝐝 𝐢𝐧 𝐩𝐡𝐚𝐫𝐦𝐚 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐭𝐫𝐞𝐧𝐝𝐬.
https://www.pharmafocusamerica.com/magazine

PROCOS has reached a major milestone in its growth journey with the completion and regulatory approval of R11, a new sta...
25/03/2026

PROCOS has reached a major milestone in its growth journey with the completion and regulatory approval of R11, a new state-of-the-art multipurpose GMP manufacturing facility.

With an investment exceeding €60 million, R11 significantly expands our capacity and flexibility in small-molecule API manufacturing, supporting clinical and commercial supply while meeting the highest quality and sustainability standards.

Designed to adapt to evolving market and regulatory needs, R11 reinforces PROCOS’ long-term strategy focused on innovation, operational excellence and responsible growth. This achievement further strengthens our position as a trusted CDMO partner worldwide.



www.procos.it

Quality in pharma is evolving—and it’s all about keeping patients at the center.In 𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 (𝐈𝐬𝐬𝐮𝐞 𝟎𝟕), 𝐌𝐢𝐥𝐝𝐫...
25/03/2026

Quality in pharma is evolving—and it’s all about keeping patients at the center.

In 𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 (𝐈𝐬𝐬𝐮𝐞 𝟎𝟕), 𝐌𝐢𝐥𝐝𝐫𝐞𝐝 𝐈. 𝐑𝐢𝐯𝐞𝐫𝐚 𝐟𝐫𝐨𝐦 𝐀𝐦𝐠𝐞𝐧 shares how Digital Quality Management Systems (DQMS) are helping organizations go beyond compliance to build smarter, more connected, and efficient quality processes.

From improving data integrity to enabling faster, risk-based decisions, DQMS is shaping the future of manufacturing excellence in life sciences.

𝐆𝐞𝐭 𝐲𝐨𝐮𝐫 𝐜𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐞𝐁𝐨𝐨𝐤 𝐚𝐧𝐝 𝐥𝐞𝐚𝐫𝐧 𝐡𝐨𝐰 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐪𝐮𝐚𝐥𝐢𝐭𝐲 𝐬𝐲𝐬𝐭𝐞𝐦𝐬 𝐚𝐫𝐞 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐭𝐡𝐞 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲:
https://www.pharmafocusamerica.com/strategy/digital-quality-management-systems

👉 𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞 𝐭𝐨 𝐝𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐧𝐨𝐰: https://www.pharmafocusamerica.com/magazine

The clinical trial landscape in Indonesia is evolving fast—and it’s creating new opportunities for global sponsors.Join ...
25/03/2026

The clinical trial landscape in Indonesia is evolving fast—and it’s creating new opportunities for global sponsors.

Join our live webinar to hear expert perspectives on recent progress, regulatory changes, and how to successfully run trials in this growing APAC market.

🗓 𝐌𝐚𝐫𝐜𝐡 𝟑𝟏, 𝟐𝟎𝟐𝟔
🕔 𝟓:𝟎𝟎 𝐏𝐌 𝐄𝐃𝐓

Whether you're planning your next study or expanding into Asia Pacific, this session is designed to help you make informed decisions.

👉 𝐒𝐚𝐯𝐞 𝐲𝐨𝐮𝐫 𝐬𝐞𝐚𝐭 𝐭𝐨𝐝𝐚𝐲—https://industry.pharmafocusamerica.com/clientemailblast/1773318474-IQVIA.html

Address

111, 112 First Floor, Block 2, White House
Hyderabad
500016

Website

Alerts

Be the first to know and let us send you an email when Pharma Focus America posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category